Stemsation International (STSN) Stock Analysis & Winston Score
Stemsation International, Inc. is a small healthcare company focused on stem cell-related products and wellness supplements. Its offerings appear to target consumers and practitioners interested in cellular health and regenerative wellness. The company operates in the specialty health products space, which sits at the edge of mainstream pharmaceutical and nutraceutical markets. Stemsation generates revenue primarily through direct product sales, though its financials show essentially no gross profit and negative returns on capital, suggesting the business is in an early or struggling stage. It appears to operate mainly in North America with a limited commercial footprint. The core risk facing Stemsation is its lack of demonstrated revenue traction and profitability — a zero gross margin signals the company has not yet built a sustainable business model, and it faces significant competition from larger, better-funded companies in both the supplement and regenerative medicine spaces.
Winston Score: 0/100 — Insufficient Data
Not enough data to score this stock reliably.
- Quality: Weak (0/30)
- Growth: Weak (2/20)
- Cash Flow: Data not available (0/10)
- Stability: Good (5/10)
- Valuation: Mixed (4/10)
- Ownership: Good (10/15)
Key Facts
Price: $0.01
Market Cap: $1M
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic


